FLNA in HCC Patients
NCT03081637 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 115
Last updated 2017-06-01
Summary
The risk of recurrence after hepatectomy for hepatocellular carcinoma (HCC) is very high. Having a predictive marker of early recurrence (ER) would be desirable to personalize the follow-up and possibly develop new targeted therapy. The aim of this study was to test the expression of Filamin A (FLNA) in a cohort of patients operated for HCC.
Conditions
Sponsors & Collaborators
-
University of Milan
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-01-01
- Primary Completion
- 2014-12-31
- Completion
- 2017-03-02
More Related Trials
-
Human Liver Explants for HIF-1 Alpha Analysis/Comparison (HIF HCC)
NCT00866957 ·Status: COMPLETED
-
Recurrence of Hepatocellular Carcinoma
NCT01520779 ·Status: COMPLETED
-
Modeling Cancer-specific Prognosis in Liver Transplantation for Hepatocellular Carcinoma (HCC)
NCT02898415 ·Status: COMPLETED
-
Long-term Management of Patients With Ruptured HCC
NCT06505291 ·Status: COMPLETED
-
Liquid Biopsy for NASH and Liver Fibrosis
NCT04677101 ·Status: COMPLETED
-
To Evaluate the Efficacy and Safety of (18F-FCH) Comparing With (18F-FDG) for Detecting Hepatocellular Carcinoma
NCT02074202 ·Status: UNKNOWN ·Phase: PHASE3
-
Detect and Expunge Concealed Tumors of the Liver
NCT06141564 ·Status: ACTIVE_NOT_RECRUITING
-
Recurrence of Liver Malignancy After Ischemia/Reperfusion Injury
NCT04257240 ·Status: COMPLETED
-
RCT of Screening Strategies Among Patients at High Risk for Developing HCC in a Safety-net Health System
NCT02312817 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment
NCT01492127 ·Status: UNKNOWN ·Phase: NA
-
The Detection of Small Early Liver Cancer With Natural History Follow up
NCT05534906 ·Status: RECRUITING
-
Generation of Organotypic Liver Cultures for the Identification of Biomarkers for the Prevention and Treatment of Liver Fibrosis
NCT06252272 ·Status: RECRUITING ·Phase: NA
-
Use of Blood Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma (HCC)
NCT05781568 ·Status: RECRUITING
-
Estimation of Functional Liver Reserve Using Cholinesterases
NCT00883454 ·Status: COMPLETED
-
Value of Negative 18FDG PET/CT in Milan Out, Up-to-seven in, HCC Transplant Candidates
NCT05276037 ·Status: RECRUITING
-
A Study of Laparoscopic Hepatectomy Versus RFA in the Treatment of Recurrent HCC
NCT03313648 ·Status: UNKNOWN ·Phase: NA
-
Primary Cell Culture of Hepatic Tumorous Cells From Routine Fine-needle Aspiration
NCT01549275 ·Status: COMPLETED
-
Study on Recurrence Monitoring of Hepatocellular Carcinoma With 5-Hydroxymethylcytosine Test
NCT03493763 ·Status: UNKNOWN
-
The Role of Serum AKR1B10 in Early Warning of Hepatocellular Carcinoma in Cirrhosis Patients
NCT07147335 ·Status: RECRUITING
-
Risk Factors and Molecular Genomics of U.S. Patients With Chronic Liver Disease and Hepatocellular Cancer
NCT01034865 ·Status: COMPLETED
-
Risk Factors of Hepatocellular Carcinomas Developed on Non-fibrotic Liver: Case-control Study (NoFlic Study)
NCT03852238 ·Status: COMPLETED
-
Serum Glycomics as Prognostic and Diagnostic Biomarkers of Disease Recurrence in Liver Transplant Recipients With Hepatocellular Carcinoma
NCT05866783 ·Status: RECRUITING
-
The Utility of Breath Biopsy as a Screening Tool for HCC
NCT04326491 ·Status: COMPLETED
-
The Clinicopathological and Prognostic Factors of Hepatocellular Carcinoma; 10 Years' Tertiary Center Experience in Egypt
NCT05047146 ·Status: COMPLETED
-
Novel Molecular Spectrometric Biomarkers in Blood Plasma as an Early Diagnostic Tool in HCC
NCT04221347 ·Status: UNKNOWN